U.S., Dec. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07284628) titled 'Vortioxetine for Newly Diagnosed Glioblastoma' on Sept. 28.
Brief Summary: There is a very urgent need to improve on the currently limited treatment options for patients with glioblastoma. Despite extensive knowledge on the molecular pathogenesis of glioblastoma obtained through genomic, transcriptional and proteomic profiling, targeted therapy efforts have not yielded major advances, likely because of interindividual and intraindividual tumor heterogeneity and redundant oncogenic pathway activation.
Accordingly, there is a strong rationale to approach the challenge of glioblastoma from a different angle, e.g., by ex vivo drug sens...